Related Experiment Video

Updated: Mar 25, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.6K

Absolute and Functional Iron Deficiency Is a Common Finding in Patients With Heart Failure and After Heart

P Przybylowski1, G Wasilewski1, K Golabek2

  • 1Department of Cardiac Surgery and Transplantology, Collegium Medicum, Jagiellonian University, Cracow, Poland.

Transplantation Proceedings
|February 27, 2016
PubMed

Insights

Anemia is common in heart failure and transplant patients due to absolute and functional iron deficiency. Screening for inflammation is crucial for managing these conditions.

Area of Science:

  • Cardiology
  • Hematology
  • Transplantation Medicine

Background:

  • Anemia is prevalent in heart failure and heart transplant recipients.
  • Both absolute and functional iron deficiency contribute to anemia in these patient groups.
  • Functional iron deficiency involves adequate iron stores but insufficient mobilization.

Purpose of the Study:

  • To determine the prevalence of absolute and functional iron deficiency.
  • To explore the relationship between iron deficiency and iron status/inflammation parameters.
  • To compare these findings in heart failure patients and heart transplant recipients.

Main Methods:

  • Assessed iron status, complete blood count, and creatinine.
  • Measured C-reactive protein, hepcidin, and hemojuvelin using commercial kits.
  • Analyzed data from 269 heart failure patients and 130 heart transplant recipients.

Main Results:

  • Absolute iron deficiency: 15% (HF) vs 30% (HTR).
  • Functional iron deficiency: 18% (HF) vs 17% (HTR).
  • Anemia prevalence higher in HTR (40% vs 22%), associated with worse kidney function.

Conclusions:

  • Absolute and functional iron deficiency affect a significant number of patients.
  • Higher C-reactive protein and hepcidin levels correlate with functional iron deficiency.
  • Patients require screening for reversible inflammation causes.
Abstract

More Related Videos

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

1.5K
Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.7K

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.2K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
574
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
830
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
743